PFE Pfizer Inc.
USHealthcareAs of 2026-07-10 16:01
Why PFE matters now
Pfizer Inc. (PFE) is a US stock in Healthcare. The latest InvestLog snapshot shows $24.17 with -0.33% on the session and $137.76B in market capitalization; recent performance reads 1-month -1.71% and YTD +1.29%.
The latest financial table shown here is Q1 2026, with revenue of $14.45B, net income of $2.69B, and EPS of $0.47. Investors can compare that operating picture with valuation signals such as P/E 19.91 and FCF yield 6.6%.
InvestLog's latest related AI research is a SEC Material Disclosure note titled "PFIZER INC files 8-K Item 5.02 executive-change disclosure". The latest indexable market news headline is "Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Hold with a median target of $27.00; recent insider activity includes BOURLA ALBERT filing A-Award; recent congressional disclosure data includes Ro Khanna Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
19.91
PEG
—
P/B
1.59
P/S
2.27
EV/EBITDA
12.33
DCF Value
$40.19
FCF Yield
6.6%
Div Yield
6.8%
Margins & Returns
Gross Margin
69.3%
Operating Margin
23.4%
Net Margin
11.8%
ROE
8.4%
ROA
3.6%
ROIC
8.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $14.45B | $2.69B | $0.47 |
| Q4 2025 | $17.56B | $-1.65B | $-0.29 |
| FY 2025 | $62.58B | $7.77B | $1.36 |
| Q3 2025 | $16.65B | $3.54B | $0.62 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$26.75
Target (Median)
$27.00
Target Range
$25.00 - $30.00
Trading Activity
Insider Trades
Congress Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
US
Exchange
—
Beta
0.29
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.